Filed Pursuant to Rule 424(b)(3)
Registration No. 333-269564
Prospectus Supplement No. 1
(To Prospectus dated February 10, 2023)
Comera Life Sciences Holdings, Inc.
7,218,726 Shares of Common Stock
This prospectus supplement no. 1 (this Prospectus Supplement) updates, amends and supplements the prospectus dated February 10, 2023 (as amended or supplemented from time to time, the Prospectus) which forms a part of the Registration Statement on Form S-1 (Registration Statement No. 333-269564) filed by Comera Life Sciences Holdings, Inc. (Holdco). Capitalized terms used in this Prospectus Supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This Prospectus Supplement is being filed to update, amend and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the SEC) on February 21, 2023 (the Current Report). Accordingly, we have attached the Current Report to this Prospectus Supplement.
This Prospectus Supplement is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus and any amendments or supplements thereto. If there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on the information in this Prospectus Supplement.
The Holdco Common Stock is listed on The Nasdaq Capital Market (Nasdaq) under the symbol CMRA and the Holdco Warrants are listed on Nasdaq under the symbol CMRAW. On February 17, 2023, the closing sale price of the Holdco Common Stock as reported on Nasdaq was $1.285 per share, and the closing sale price of the Holdco Warrants as reported on Nasdaq was $0.065 per warrant.
Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in Risk Factors beginning on page 7 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or passed upon the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is February 21, 2023.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 14, 2023
Comera Life Sciences Holdings, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
12 Gill Street
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (617) 871-2101
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock||CMRA||The Nasdaq Stock Market LLC|
|Warrants||CMRAW||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02|| |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 14, 2023, the Board of Directors (the Board) of Comera Life Sciences Holdings, Inc. (the Company) met to determine the non-equity incentive compensation to be paid to each of Jeffrey Hackman, the Companys Chairman, President and Chief Executive Officer, Michael Campbell, the Companys Chief Financial Officer and Neal Muni, the Companys Chief Operating Officer (together the Named Executive Officers) in respect of their achievement of 2022 performance objectives. In furtherance of the Companys cash conservation efforts and to better align the interests of the Named Executive Officers with those of the Companys stockholders, the Board elected to grant options (the Options) to purchase shares of the Companys common stock, $0.0001 par value per share (the Common Stock) to the Named Executive Officers in lieu of performance-based cash compensation. The Options were granted under the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the 2022 Plan) and have an exercise price of $1.30 per share, the closing price of the Common Stock on the date of grant. Twenty-five percent of the shares underlying the Options vest on February 14, 2024, with the remaining shares vesting on a monthly basis on the 14th day of each month thereafter, in each case, subject to continuous service to the Company, such that the Options shall be fully vested on February 14, 2027.
The Company filed a Registration Statement on Form S-1 with the Securities and Exchange Commission (the SEC) on February 3, 2023, as amended on February 8, 2023, which was declared effective on February 10, 2023 (File No. 333-269564) (the Registration Statement). The Summary Compensation Table included in the Registration Statement did not include non-equity incentive plan compensation paid to the Named Executive Officers for fiscal 2022 because 2022 non-equity incentive plan compensation had not yet been determined. In accordance with Item 5.02(f) of Form 8-K, the table below is updated to provide this information.
SUMMARY COMPENSATION TABLE
Name and Principal Position
|Year||Salary ($)||Bonus ($)||Option
Jeffrey Hackman Chief Executive Officer (3)
Michael Campbell, Chief Financial Officer(4)
Neal Muni, MD Chief Operating Officer(5)
Amounts reflect the full grant-date fair value of stock options granted, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. For more information see footnote 2 to our financial statements for the years ended December 31, 2021 and 2020 Basis of Presentation and Significant Accounting Policies Stock-Based Compensation Expense found elsewhere in this Report.
In furtherance of the Companys cash conservation efforts and to align the interests of the Named Executive Officers with those of the Companys stockholders, the Board granted options to purchase shares of the Companys common stock to the Named Executive Officers in lieu of performance-based cash compensation for the fiscal year ended December 31, 2022. The following table sets forth the number of options granted to each Named Executive Officer on February 14, 2023:
Mr. Hackman became our Chief Executive Officer on September 1, 2021.
Mr. Campbell became our Chief Financial Officer on June 15, 2022.
Mr. Muni became our Chief Operating Officer on September 13, 2021.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: February 21, 2023||COMERA LIFE SCIENCES HOLDINGS, INC.|
/s/ Michael Campbell
|Title:||Executive Vice President and Chief Financial Officer|